Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
The Journal of Rheumatology|October 4, 2011
Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritisLisa K Stamp, Murray L Barclay, John L O'Donnell, et al.
Clinical Pharmacokinetics|March 14, 2013
A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cellsJulia Korell, Lisa K Stamp, Murray L Barclay, et al.
Rheumatology (Oxford, England)|April 28, 2012
Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practiceLisa K Stamp, Murray L Barclay, John L O'Donnell, et al.
British Journal of Clinical Pharmacology|October 10, 2015
Predicting allopurinol response in patients with goutDaniel F B Wright, Stephen B Duffull, Tony R Merriman, et al.
The American Journal of Gastroenterology|March 29, 2008
Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjectsRobert W Bentley, Jacqui I Keenan, Richard B Gearry, et al.
Internal Medicine Journal|November 24, 2023
Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosingPaula E Keating, Barry D Hock, Stewart M Smith, et al.
Internal Medicine Journal|August 10, 2018
Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assaysMurray L Barclay, Shwan Karim, Esther T Johanna Helms, et al.
Mutation Research|February 11, 2010
Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease populationChristopher M Triggs, Karen Munday, Rong Hu, et al.
Therapeutic Drug Monitoring|July 30, 2015
Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or InfliximabBarry D Hock, Lisa K Stamp, Matthew W Hayman, et al.
Arthritis Research & Therapy|November 18, 2018
How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based doseLisa K Stamp, Peter T Chapman, Murray L Barclay, et al.
Pageof 10